Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study

This was a phase 2, multicenter, randomized, double-blind, placebo-controlled, open-label comparator study to investigate the efficacy and safety of esaxerenone (CS-3150), a novel non-steroidal mineralocorticoid receptor blocker, in Japanese patients with essential hypertension. Eligible patients (n...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Sadayoshi Ito, Hiroshi Itoh, Hiromi Rakugi, Yasuyuki Okuda, Satoru Yamakawa
Formato: Artigo
Idioma:inglés
Publicado: 2019
Acceso en liña:https://doi.org/10.1038/s41371-019-0207-x
https://www.nature.com/articles/s41371-019-0207-x.pdf
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!